Back to Directory
Insulin Glulisine
Performance & EnduranceRapid-acting insulin analog marketed as Apidra.
Key Benefits
- ✓Rapid mealtime insulin
- ✓Flexible dosing
- ✓Fast onset
- ✓Good postprandial control
Dosing Information
Dosage Range
Variable
Frequency
With meals
Typical Duration
Lifelong for T1D
Detailed Protocol
Administered subcutaneously with meals or via pump. Dosed based on carbohydrate intake and blood glucose. Can give immediately before or after meals.
About Insulin Glulisine
Insulin glulisine (Apidra) is a rapid-acting insulin analog with asparagine at B3 replaced by lysine and lysine at B29 replaced by glutamic acid. Similar rapid action to other rapid-acting analogs.
Research Notes
FDA-approved in 2004. Third rapid-acting insulin analog after lispro and aspart. Similar efficacy and safety to other rapid analogs. Standard option for mealtime coverage.
Potential Side Effects
- •Hypoglycemia
- •Weight gain
- •Injection site reactions
- •Allergic reactions
Always consult with a healthcare professional before starting any peptide therapy.